Výsledky vyhledávání - "Thangrarajh Mugunthan"

Abiraterone acetate plus Prednisone/Prednisolone compared with Enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real‐world data (ACES)

Autor: Prantik Das, Cristina Martin-Fernandez, Sarah K. Taylor, Chandrani Mallik, Michael Jones, James Price, Colin Ward, Akram Ali, Thangrarajh Mugunthan

Publikováno v: BJUI Compass. 1:21-31

Abiraterone acetate combined with Prednisone/Prednisolone (AA+P) and Enzalutamide (ENZ) have proven survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC) in chemotherapy-naïve and prior chemotherapy patients. There hav

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::028c9478701e49262a2436c6d7e81c9e
https://doi.org/10.1002/bco2.11

Zobrazit plný text záznamu

First UK experience of apalutamide in metastatic and non-metastatic prostate cancer outside of clinical trials

Autor: Prantik Das, Rania Mohammed, Naveed Sarwar, Omar Din, Ankit Jain, Jessica Davies, Thangrarajh Mugunthan, Ajith Nair, Aruni Ghose, Seheli Bandyopadhyay, Roopesh Krishnappa, Pooja Iyer, Lauren Jones, Nikhil Vasdev, Maja Moldawa, Rebecca Devine, Robert Hughes, Anand Sharma

Publikováno v: Journal of Clinical Oncology. 41:106-106

106 Background: Apalutamide plus androgen deprivation therapy(ADT) has been approved as a treatment option for castrate resistant non metastatic prostate cancer (nmCRPC) with a high risk of developing metastatic disease. It has also demonstrated bene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d196e01613d0de87c03fbe898927db34
https://doi.org/10.1200/jco.2023.41.6_suppl.106

Zobrazit plný text záznamu

Abiraterone acetate plus prednisone/prednisolone compared with enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real-world data (ACES)

Autor: Chandrani Mallick, Cristina Martin-Fernandez, Prantik Das, Akram Ali, James Price, Michael Jones, Thangrarajh Mugunthan

Publikováno v: Journal of Clinical Oncology. 37:303-303

303 Background: Abiraterone acetate (a prodrug of abiraterone, which is a selective inhibitor of androgen biosynthesis) combined with prednisone/prednisolone (AA+P) and enzalutamide (ENZ) (an androgen-receptor–signalling inhibitor) have proven surv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::04d0fcac8cd9647992800ee2f6bbbfbb
https://doi.org/10.1200/jco.2019.37.7_suppl.303

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání